Literature DB >> 25088833

Comparison of perfusion- and diffusion-weighted imaging parameters in brain tumor studies processed using different software platforms.

Mikhail V Milchenko1, Dhanashree Rajderkar2, Pamela LaMontagne2, Parinaz Massoumzadeh2, Ronald Bogdasarian2, Gordon Schweitzer2, Tammie Benzinger2, Dan Marcus2, Joshua S Shimony2, Sarah Jost Fouke3.   

Abstract

RATIONALE AND
OBJECTIVES: To compare quantitative imaging parameter measures from diffusion- and perfusion-weighted imaging magnetic resonance imaging (MRI) sequences in subjects with brain tumors that have been processed with different software platforms.
MATERIALS AND METHODS: Scans from 20 subjects with primary brain tumors were selected from the Comprehensive Neuro-oncology Data Repository at Washington University School of Medicine (WUSM) and the Swedish Neuroscience Institute. MR images were coregistered, and each subject's data set was processed by three software packages: 1) vendor-specific scanner software, 2) research software developed at WUSM, and 3) a commercially available, Food and Drug Administration-approved, processing platform (Nordic Ice). Regions of interest (ROIs) were chosen within the brain tumor and normal nontumor tissue. The results obtained using these methods were compared.
RESULTS: For diffusion parameters, including mean diffusivity and fractional anisotropy, concordance was high when comparing different processing methods. For perfusion-imaging parameters, a significant variance in cerebral blood volume, cerebral blood flow, and mean transit time (MTT) values was seen when comparing the same raw data processed using different software platforms. Correlation was better with larger ROIs (radii ≥ 5 mm). Greatest variance was observed in MTT.
CONCLUSIONS: Diffusion parameter values were consistent across different software processing platforms. Perfusion parameter values were more variable and were influenced by the software used. Variation in the MTT was especially large suggesting that MTT estimation may be unreliable in tumor tissues using current MRI perfusion methods.
Copyright © 2014 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; Tumor imaging; cerebral diffusion; cerebral perfusion

Mesh:

Year:  2014        PMID: 25088833      PMCID: PMC4607045          DOI: 10.1016/j.acra.2014.05.016

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  39 in total

Review 1.  Twenty-five pitfalls in the analysis of diffusion MRI data.

Authors:  Derek K Jones; Mara Cercignani
Journal:  NMR Biomed       Date:  2010-08       Impact factor: 4.044

2.  Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.

Authors:  James R Fink; Robert B Carr; Eiji Matsusue; Ramesh S Iyer; Jason K Rockhill; David R Haynor; Kenneth R Maravilla
Journal:  J Magn Reson Imaging       Date:  2011-10-14       Impact factor: 4.813

3.  Comparison of apparent diffusion coefficient values among different MRI platforms: a multicenter phantom study.

Authors:  Ali Sami Kıvrak; Yahya Paksoy; Cengiz Erol; Mustafa Koplay; Seda Özbek; Fatih Kara
Journal:  Diagn Interv Radiol       Date:  2013 Nov-Dec       Impact factor: 2.630

4.  Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.

Authors:  C P Geer; J Simonds; A Anvery; M Y Chen; J H Burdette; M E Zapadka; T L Ellis; S B Tatter; G J Lesser; M D Chan; K P McMullen; A J Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-24       Impact factor: 3.825

5.  Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.

Authors:  H Thomsen; E Steffensen; E-M Larsson
Journal:  Acta Radiol       Date:  2011-11-23       Impact factor: 1.990

6.  Investigating brain tumor differentiation with diffusion and perfusion metrics at 3T MRI using pattern recognition techniques.

Authors:  Patricia Svolos; Evangelia Tsolaki; Eftychia Kapsalaki; Kyriaki Theodorou; Kostas Fountas; Ioannis Fezoulidis; Ioannis Tsougos
Journal:  Magn Reson Imaging       Date:  2013-07-30       Impact factor: 2.546

7.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.

Authors:  Benjamin M Ellingson; Mark G Malkin; Scott D Rand; Pete S LaViolette; Jennifer M Connelly; Wade M Mueller; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2010-08-27       Impact factor: 4.130

Review 8.  Diffusion-weighted MRI as a biomarker for treatment response in glioma.

Authors:  Kathleen M Schmainda
Journal:  CNS Oncol       Date:  2012-11

9.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.

Authors:  T Sugahara; Y Korogi; S Tomiguchi; Y Shigematsu; I Ikushima; T Kira; L Liang; Y Ushio; M Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

10.  Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.

Authors:  Leland S Hu; Jennifer M Eschbacher; Joseph E Heiserman; Amylou C Dueck; William R Shapiro; Seban Liu; John P Karis; Kris A Smith; Stephen W Coons; Peter Nakaji; Robert F Spetzler; Burt G Feuerstein; Josef Debbins; Leslie C Baxter
Journal:  Neuro Oncol       Date:  2012-05-03       Impact factor: 12.300

View more
  5 in total

1.  Heterogeneous Optimization Framework: Reproducible Preprocessing of Multi-Spectral Clinical MRI for Neuro-Oncology Imaging Research.

Authors:  Mikhail Milchenko; Abraham Z Snyder; Pamela LaMontagne; Joshua S Shimony; Tammie L Benzinger; Sarah Jost Fouke; Daniel S Marcus
Journal:  Neuroinformatics       Date:  2016-07

2.  Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.

Authors:  Gian Marco Conte; Antonella Castellano; Luisa Altabella; Antonella Iadanza; Marcello Cadioli; Andrea Falini; Nicoletta Anzalone
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

3.  Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Authors:  Zachary S Kelm; Panagiotis D Korfiatis; Ravi K Lingineni; John R Daniels; Jan C Buckner; Daniel H Lachance; Ian F Parney; Rickey E Carter; Bradley J Erickson
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-26

4.  7T MRI subthalamic nucleus atlas for use with 3T MRI.

Authors:  Mikhail Milchenko; Scott A Norris; Kathleen Poston; Meghan C Campbell; Mwiza Ushe; Joel S Perlmutter; Abraham Z Snyder
Journal:  J Med Imaging (Bellingham)       Date:  2018-01-08

Review 5.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.